



# Medical Coverage Policy

Effective Date .....05/15/2024

Next Review Date .....05/15/2025

Coverage Policy Number..... 0070

## Allergy Testing and Non-Pharmacologic Treatment

### Table of Contents

Overview .....	2
Coverage Policy.....	2
Health Equity Considerations.....	5
General Background .....	5
Medicare Coverage Determinations .....	14
Coding Information.....	15
References .....	18
Revision Details .....	26

### Related Coverage Resources

- [Complementary and Alternative Medicine](#)
- [Grass Pollen Sublingual Products](#)
- [Odactra](#)
- [Omalizumab](#)
- [Peanut \(arachis hypogaea\) allergen powder-dnfp](#)
- [Ragwitek](#)

### INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers

*must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.*

## Overview

This Coverage Policy addresses testing and non-pharmacologic treatment for allergy. Allergy testing may be in vivo (i.e., testing on or near the patient and monitoring the patient's physiological response(s)) or in vitro procedures (i.e., analyzing the individual's serum). Non-pharmacologic immunotherapy may be allergen immunotherapy by subcutaneous injection and sublingual antigen extract drop immunotherapy preparations.

## Coverage Policy

### Testing:

#### Medically Necessary

**The following in vivo allergy tests are considered medically necessary:**

- prick/puncture allergy testing to diagnose suspected immunoglobulin E (IgE)-mediated hypersensitivity to inhalants, foods, hymenoptera (e.g., bee venom), drugs and/or chemicals
- intradermal allergy testing to diagnose suspected immunoglobulin E (IgE)-mediated hypersensitivity to inhalants, hymenoptera (e.g., bee venom), drugs and/or chemicals
- skin patch testing to diagnose suspected contact allergic dermatitis
- photo patch testing to diagnose suspected contact photosensitization (e.g., photoallergic contact dermatitis)
- skin patch testing performed prior to joint replacement surgery for **EITHER** of the following:
  - previous surgery involving an implant with complications suspected to be caused by metal allergy
  - history of severe localized (i.e., blistering, hives, and/or extensive rash) or systemic cutaneous reaction to metals
- skin patch testing performed following joint replacement surgery when **BOTH** of the following criteria are met:
  - presence of symptoms attributable to metal allergy/hypersensitivity (e.g., pain, swelling, cutaneous rash, loss of function)
  - etiology other than metal allergy/hypersensitivity (e.g., infection, mechanical failure) have been ruled out
- food/food additive ingestion double-blind challenge/provocation to diagnose suspected IgE-mediated hypersensitivity if skin testing is negative or equivocal, despite a history and physical findings suggestive of hypersensitivity
- drug provocation/bronchial challenge test to diagnose suspected IgE-mediated hypersensitivity when there is a confirmed history of allergy to a drug, and the individual requires the particular drug for treatment of a diagnosed condition, and there is no effective alternative drug available

- skin serial endpoint titration (SET) for determination of a safe starting dose for testing or immunotherapy when there is potential for the specific allergen in question to produce a severe systemic reaction or anaphylaxis (such as with bee venom)

When in vivo allergy testing is considered medically necessary as noted in the criteria above, the following frequency limits apply (rolling 12 months):

- percutaneous (scratch, puncture, prick) testing (CPT code 95004): 80 units
- intracutaneous (intradermal) testing (CPT code 95024): 40 units

**In vivo allergy testing that exceeds the following limits is not covered or reimbursable:**

- percutaneous (scratch, puncture, prick) testing (CPT code 95004): 80 units
- intracutaneous (intradermal) testing (CPT code 95024): 40 units

**In vitro allergy testing (blood serum analysis, e.g., ImmunoCAP®, radioallergosorbent test [RAST], multiple radioallergosorbent test [MAST], fluorescent allergosorbent test [FAST], paper radioimmunosorbent test [PRIST], radioimmunosorbent test [RIST], enzyme-linked immunosorbent assay [ELISA], MRT [modified RAST], and VAST) is considered medically necessary when ANY of the following criteria is met:**

- for the diagnosis of suspected IgE-mediated food or inhalant allergies for one of the following indications:
  - individual with severe dermatographism, ichthyosis or generalized eczema
  - individual who cannot be safely withdrawn from medications that interfere with skin testing (such as long-acting antihistamines, tricyclic antidepressants)
  - individual who has a history of a previous systemic reaction to skin testing
  - individual in whom skin testing was equivocal/inconclusive and in vitro testing is required as a confirmatory test
- as an alternative to skin testing for the evaluation of cross-reactivity between insect venoms
- when specific IgE immunoassays are used as adjunctive testing for disease activity of allergic bronchopulmonary aspergillosis and certain parasitic diseases

When in vitro allergy testing is considered medically necessary as noted in the criteria above, the following frequency limit applies (rolling 12 months):

- allergen specific IgE; quantitative or semiquantitative testing (CPT code 86003): 80 units

**Allergen specific IgE; quantitative or semiquantitative testing that exceeds 80 units is not covered or reimbursable.**

**In vitro metal lymphocyte transformation testing (LTT) performed prior to joint replacement surgery is considered medically necessary when ALL of the following criteria are met:**

- previous surgery involving an implant, with complications suspected to be caused by metal allergy
- history of severe localized (i.e., blistering, hives, and/or extensive rash) or systemic cutaneous reaction to metals
- skin patch testing is contraindicated or results are equivocal

**In vitro metal lymphocyte transformation testing (LTT) performed following joint replacement surgery is considered medically necessary when ALL of the following criteria are met:**

- presence of symptoms attributable to metal allergy/hypersensitivity (e.g., pain, swelling, cutaneous rash, loss of function)
- etiology other than metal allergy/hypersensitivity (e.g., infection, mechanical failure) have been ruled out
- skin patch testing (detailed above) is contraindicated or results are equivocal

**In vivo or in vitro allergy testing is not covered or reimbursable for any other indication.**

**Leukocyte histamine release (LHR) in vitro allergy testing for the diagnosis or management of allergic disease is considered experimental/investigational or unproven.**

**Bead-based epitope assay (e.g., VeriMAP™ Peanut Dx, VeriMAP™ Peanut Sensitivity) is not covered or reimbursable.**

**Treatment:**

**Medically Necessary**

**Subcutaneous allergen immunotherapy is considered medically necessary for the treatment of allergic asthma and allergic rhinitis (with or without allergic conjunctivitis) when ALL of the following criteria are met:**

- presence of specific immunoglobulin E (IgE) to the allergen in question demonstrated by skin testing or serum/in-vitro testing
- hypersensitivity cannot be managed by medications or allergen avoidance
- professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, single or multiple antigens (CPT® code 95165) up to a maximum of 150 doses per year (i.e., rolling 12 months).

**Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, single or multiple antigens (CPT® code 95165) that exceeds a maximum of 150 doses per year (i.e., rolling 12 months) are not covered or reimbursable.**

**Subcutaneous allergen immunotherapy is considered medically necessary for the treatment of Hymenoptera (e.g., hornet, wasp, bee, fire ant) venom allergy when ALL of the following criteria are met:**

- history of systemic reaction to a Hymenoptera sting
- presence of Hymenoptera-specific IgE demonstrated by skin testing or serum/in-vitro testing
- professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, single or multiple antigens (CPT codes 95145-95149, 95170)

**Sublingual antigen extract drop immunotherapy preparations are not covered or reimbursable.**

**Note:** Please refer to Drug and Biologic Coverage Policies IP0515: Grass Pollen Sublingual Products, IP0516: Odactra, IP0518: Ragwitek, and 2004: Peanut (*arachis hypogaea*) allergen powder-dnfp for information regarding FDA-approved non-subcutaneous allergen immunotherapy.

## Health Equity Considerations

The American Academy of Allergy, Asthma and Immunology (AAAAI) published a workgroup report on health disparities in allergic and immunologic conditions in racial and ethnic underserved populations. Allergic rhinitis (AR) is underdiagnosed and underappreciated in certain racial and ethnic populations. Black children without a personal or family history of atopy had a higher odds of sensitization to any allergen as well as discrete sensitization to mold, cockroach, grass, weed and tree pollen compared to white children. Latino populations are also significantly affected by AR and under diagnosed in Puerto Rican and urban populations. Clinical studies have demonstrated that low-income and minority groups are less likely to receive allergen immunotherapy (AIT) and Medicaid insurance is associated with more emergency room care for acute nasal symptoms compared to private insurance. The studies highlight that additional burdens faced by lower income families can contribute to a lack of resources necessary to adhere to AIT rigorous schedules. Disparities in food allergies (FA) are predominately seen among under-represented racial and ethnic groups and lower income populations in the United States, with higher rates of FA-related anaphylaxis and ED visits. Black children have higher odds of wheat, soy, corn, fish, and shellfish allergy, and Hispanic children have higher odds of corn, fish, and shellfish allergy. Children belonging to under-represented racial and ethnic groups are less likely to have prescribed FA action plans, have a shorter duration of specialist follow-up, and have higher rates of FA related anaphylaxis and ED visits. Food insecurity is a risk factor in milk and egg allergy and was associated with lower health literacy (Davis, et al., 2021).

## General Background

Allergies result from an overreaction of the immune system to foreign substances (e.g., pollen, dust, mold, animal fur or dander, stinging insect venom, food). An allergy develops when the body is exposed to a substance that prompts the initiation of an immune response. This response involves the production of antibodies, called immunoglobulins (Igs), which are directed against proteins of the foreign substance, called allergens or antigens. While there are five classes of immunoglobulins, it is IgE that is typically involved in allergic reactions. When an allergy-prone individual is exposed to a specific antigen, B-cells produce an IgE that recognizes only that antigen. This antigen-specific IgE then binds to receptors on specific cells that reside in tissue (mast cells) or circulate in the blood (basophils). Upon re-exposure to the same antigen, the antigen-specific IgE binds to membrane receptors on tissue mast cells and blood basophils and then releases a series of chemicals (histamine, leukotrienes, cytokines and proteases) that regulate the allergic reaction. While the allergic reaction begins immediately, signs and symptoms of the reaction may occur within seconds or minutes (immediate hypersensitivity), may be delayed for several hours (delayed hypersensitivity), or may involve both early-and late-phase reactions.

### **Testing**

Allergy tests are performed to verify or exclude the presence of IgE-mediated hypersensitivity and to identify the causative allergen(s). Testing may involve in vivo procedures, which determine the presence of specific IgE by administering an IgE-specific allergen into, on or near the patient and monitoring the patient's physiological response(s). Allergy tests may also be in vitro procedures that determine the presence of specific IgE or elevated total IgE by analyzing patient serum.

The allergy testing methods and recommendations detailed below are based primarily on practice parameters and recommendations from the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the American Academy of Otolaryngic Allergy (AAOA).

### **In Vivo Allergy Testing**

The number/frequency of tests needed to diagnose an individual with allergies is varied. Up to 80 percutaneous skin tests may be necessary to diagnose food allergies (scratch, puncture, prick, CPT code 95004). Up to 40 intracutaneous (intradermal) tests with allergenic extracts (CPT code 95024) is considered appropriate. If allergy skin tests cannot be performed due to a skin condition, etc., up to 40 allergen-specific IgE tests may be considered appropriate (CPT code 86003). Frequency is based on a rolling 12 month basis.

In vivo allergy tests fall into two general categories: skin tests and organ challenge (or provocation) tests. Both are designed to confirm hypersensitivity and identify the antigen(s) responsible for the allergic reaction. The most common in vivo allergy tests are outlined below. The efficacy of some in vivo allergy tests has not been firmly established, due to the limited numbers of well-designed clinical trials. Few prospective studies are available, and evidence is primarily in the form of expert opinion.

Skin testing can be utilized to detect immediate hypersensitivity (IgE-dependent reactions) and delayed hypersensitivity (cell-mediated immune reactions). The two major methods of skin testing for IgE-mediated disease include the prick-puncture test and the intradermal test. A positive response to skin testing is typically indicated by the presence of a wheal and/or flare at the test site. Scratch testing is no longer a recommended allergy testing procedure, due to reproducibility issues and the high incidence of false-positive reactions.

Skin testing is contraindicated in patients with severe dermatographism (allergy in which a pale, raised wheal is produced when skin is scratched), ichthyosis (condition in which skin is dry and scaly, resembling fish skin) or generalized eczema; in patients who cannot be withdrawn from medications that interfere with skin testing (such as long-acting antihistamines and tricyclic antidepressants); and in patients who have a history of a previous systemic reaction to skin testing.

Prick/puncture tests are used for confirmation of clinical immediate hypersensitivity induced by inhalant and food allergens. Skin prick/puncture tests are generally considered the most specific screening method for detecting the presence of IgE antibodies in patients with appropriate exposure histories. These tests may also be used in the diagnosis of drug and chemical hypersensitivity reactions. Prick/puncture tests are generally less sensitive than intradermal testing. For inhalant allergies, prick/puncture tests have been shown to correlate better with the presence of clinical allergy. Skin testing is considered the gold standard for the diagnosis of IgE-mediated allergic disease. The Joint Task Force of Allergy, Asthma, and Immunology recommends skin prick/puncture tests as the primary test for the diagnosis of IgE-mediated allergic diseases.

Intradermal or intracutaneous tests are generally used when increased sensitivity is the main goal of testing (i.e., when prick/puncture tests are negative despite a compatible history of exposure). Intradermal tests are more sensitive but less specific than prick/puncture tests for most allergens but are superior to other skin tests for assessing hypersensitivity to hymenoptera (stinging insects) and penicillin or allergens of lower potency. Intradermal testing for food allergies is not recommended because of the high rate of false positive test results and the potential for anaphylaxis.

Repeat skin testing with multiple antigens is not indicated on a regular basis (e.g., yearly). Indications for repeat testing include changing symptoms, new exposures, or 3–5 years of venom immunotherapy.

Patch testing is used to determine the presence or cause of delayed hypersensitivity reactions originating on the skin. It is primarily used to assess allergic contact dermatitis, an eczema-type, immunologically-mediated skin reaction which is largely cell-mediated but may contain an IgE-mediated component. The clinical utility of patch testing to identify allergic reactions other than those originating on the skin (such as inhalants or food allergens) has not been determined. It is estimated that 20–30 antigens used in the panel of patch tests will identify between 50% and 70% of the clinically relevant causes of contact dermatitis.

Certain substances may elicit an allergic reaction only when exposed to light. In photo patch testing, the suspected chemical or medication is applied in two separate areas. One of the areas is exposed to a range of ultraviolet type A light and then examined for the presence of a reaction. Testing is considered positive if only the area that has been exposed to the ultraviolet light demonstrates an allergic reaction.

Oral challenge may be used to confirm or diagnose IgE-mediated hypersensitivity to specific foods, food additives and preservatives, or drugs. Food challenge is time-consuming and associated with the potential for anaphylaxis. Simpler measures, such as skin tests and elimination of suspected foods from the diet, are typically tried first. If skin tests are negative or equivocal and inconsistent with a history suggestive of food allergy, and symptoms abate after elimination of suspected foods, one food at a time is added back into the diet (open food challenge) until symptoms recur. Blinded, controlled food challenge (by ingestion) may be undertaken when skin tests are negative or inconsistent with a history that suggests food allergy. Sublingual food allergy testing, in which the food in question is placed under the tongue and not ingested, is an unproven testing method (see "provocation-neutralization," below). Double-blind food challenges are typically reserved for a select subset of patients.

Drug provocation/bronchial challenge testing is typically undertaken only if the need to confirm or exclude hypersensitivity outweighs the risk of severe reaction. This may occur in patients who have a history of allergy to a particular drug for which there is no effective alternative but who need that drug for treatment. Bronchial challenge testing is used in the diagnosis and management of asthma to quantify allergic airway responsiveness to pharmacological agents, such as methacholine or histamine. Bronchial provocation/challenge testing with extracts of common aeroallergens such as dust or ragweed, however, has no established clinical value and offers no additional clinical information beyond that obtained by a well-taken clinical history and a carefully performed skin test.

Serial endpoint titration (SET) is a variation of intradermal skin testing in which increasing doses of antigen are used to determine the concentration at which the reaction changes from negative to positive (i.e., the endpoint). SET has been used as an alternative to skin prick testing or in vitro testing and has also been used to guide initiation of immunotherapy, with the endpoint dilution used as the starting dose. Although not considered a replacement for skin testing, SET may be indicated for determination of a safe starting dose for testing or immunotherapy when there is potential for the specific allergen in question to produce a severe systemic reaction or anaphylaxis (such as with bee venom).

### **In Vitro Allergy Testing**

The discovery of the role of IgE in clinical allergy testing resulted in the development of in vitro diagnostic assays to test for allergen sensitivity. The first immunoassays were developed to quantify the serum concentration of total IgE. In normal individuals, IgE is usually present at low

levels; 130 ng/ml represents the upper limit of the normal range. However, a significant number of asymptomatic normal individuals, such as those with parasitic diseases or with depressed cell-mediated immunity, exceed this level. Also, some allergic patients may exhibit normal total IgE levels in the presence of elevated levels of specific IgE. Methods were therefore developed to assay allergen-specific IgE. The radioallergosorbent test (RAST) system was developed for in vitro measurement of specific IgE in a patient's serum. Other in vitro tests for specific IgE have been developed and employ the same principles as the RAST but use an enzymatic (MAST) or fluorogenic (FAST) detection system in place of a radioactive label.

In vitro tests that screen for multiple allergens in a single assay (Phadiatop<sup>®</sup>, Pharmacia Diagnostics) or that can be used in an automated system (ImmunoCAP<sup>®</sup>, Pharmacia Diagnostics) have been developed. The ImmunoCAP is designed as a "sandwich" immunoassay. The sensitivity and specificity of the ImmunoCAP compares favorably with those of the modified PhadezymRAST<sup>®</sup> system. Results from studies have indicated that, when compared to skin prick testing as the gold standard, the ImmunoCAP system has been shown to have a greater sensitivity (80–95%) than RAST and to have similar specificity (85%). Other modified versions of the RAST test include the PRIST, RIST, MRT (modified RAST) and ELISA IgE tests.

The overall sensitivity of in vitro immunoassays compared with prick/puncture skin tests has been reported to range from 50–90%, with an average of about 70–75% from most studies. Skin testing, therefore, continues to be the preferred method for the diagnosis of IgE-mediated sensitivity. According to practice parameters issued by the AAAI, selective use of in vitro tests may be justified for patients in whom skin testing is inappropriate. Situations in which specific IgE immunoassays may be appropriate include:

- testing of patients with severe dermatographism, ichthyosis or generalized eczema
- testing in patients who cannot be withdrawn from medications that interfere with skin testing (patients receiving long-acting antihistamines or tricyclic antidepressants)
- testing in patients who have a clinical history suggesting an unusually greater risk for anaphylaxis or who have had a previous systemic reaction to skin testing
- testing of patients with mental or physical impairments

When there is a clear history of sting anaphylaxis and skin test results are negative, then serum IgE antibodies should be measured, and if necessary, skin tests should be repeated after 3 to 6 months (Kowal and DuBuske, 2021; Golden, et al., 2017).

It should be noted that specific IgE immunoassays do not have sufficient sensitivity for absolute positive prediction of anaphylactic sensitization to venoms, penicillin and other drugs. This method of testing should not be used to provide definitive diagnoses, due to the potential for serious consequences resulting from a false-negative outcome. Allergen-specific IgE immunoassays provide neither diagnostic nor prognostic information when measured in the cord blood of newborn infants.

### **Arthroplasty Implants: In Vitro Testing for Metal Allergy/Hypersensitivity**

Metal implants are widely used in orthopedic surgery for joint arthroplasty and fracture fixation. Metallic implants are frequently composed of stainless steel, Vitallium, titanium, Zirconium, and cobalt-chromium-molybdenum alloys. These alloys are typically composed of metals including aluminum, chromium, cobalt, nickel, molybdenum, vanadium, titanium and iron. Intolerance reactions to metal implants include dermatitis, impaired wound healing, effusion, pain, or loosening. It is important to distinguish between cutaneous contact sensitivity and sensitivity to implanted devices. Local reactions at the time of contact (e.g., rash, urticarial, swelling) are seen with hypersensitivity related to cutaneous contact with metallic objects such as jewelry. Metal contact allergy/hypersensitivity is quite common, and there is insufficient evidence to demonstrate



that this places patients at increased risk of developing complications following orthopedic implant procedures. Routine testing for metal allergy prior to joint implantation therefore has not been established. There may be a role such testing, however, in patients with a history of severe localized (e.g., hives, blistering, extensive rash) or systemic cutaneous reactions, or in those with a history of complications suspected to be caused by metal allergy with a prior implant.

Evidence evaluating the relationship between metal allergy/sensitivity and implant outcomes is limited. In reviewing the approach to the clinical work-up of patients with putative allergic disease to metallic orthopedic implants, Thyssen et al. (2011) stated that the overall risk of developing extracutaneous allergic reactions following total hip arthroplasty is comparable in metal patch test positive and negative subjects. It has been proposed that up to 5% of total joint arthroplasty failure within seven years of surgery may be caused by debris-induced immune reactivity, including delayed-type hypersensitivity reactions to metals. The authors recommend that clinicians should not perform routine patch testing prior to surgery unless the patient has already had implant surgery with complications suspected to be allergic or has a history of clinical metal intolerance of sufficient magnitude to be of concern. In this case it would be advisable to avoid an implant containing metal(s) that the patient reacted to during allergy testing. The authors propose that the clinical work-up of a patient suspected of having an allergic reaction to a metal implant would include patch testing and possibly in vitro testing. The toxicity of some metals may hamper in vitro testing, and patch testing may allow screening for more metals. In vitro testing may be useful, however, in doubtful cases and offer quantitative estimates.

Granchi et al. (2012) published results of a systematic review and meta-analysis of metal sensitivity testing in patients undergoing total joint arthroplasty, to assess the risk of developing metal hypersensitivity postoperatively and the impact on outcomes, and also to investigate the advantages of performing hypersensitivity testing. A total of 22 studies (3654 patients) met the inclusion criteria. Fourteen studies were eligible for calculating the risk of metal allergy in patients undergoing joint replacement. The frequency of positive tests increased following joint replacement, particularly in patients with implant failure or a metal-on-metal coupling. The probability of developing a metal allergy was higher postoperatively (odds ratio [OR] 1.52 (95% confidence interval [CI] 1.06-2.31,  $p=0.02$ ). Ten studies were eligible to calculate the risk of metal allergy according to the status of the replacement. The probability of having a metal allergy was more than double in patients who had a failed replacement than in those with a stable replacement (OR 2.76 [95% CI 1.14-6.70,  $p=0.02$ ) There was significant heterogeneity between studies, however, and no predictive value regarding the status of the replacement could be attributed to the testing results for metal sensitization. The meta-analysis confirmed that the probability of developing a metal allergy is higher post-operatively, and the risk is even greater when failed replacements are compared with stable replacements.

In terms of defining the advantage of hypersensitivity testing, the findings demonstrated that pre- or post-operative screening has no predictive value. The authors noted, however, that most papers concluded that hypersensitivity testing should be performed preoperatively in patients with a history of metal allergy and should be performed in those with a failed replacement when hypersensitivity is suspected, after excluding infection and mechanical failure. The authors stated that the question of which test is best is debatable, since both in vitro and in vivo testing have advantages and disadvantages. Limitations of large-scale application of in vitro testing include the cost and need for specialized laboratories. The patch test is considered the reference method for diagnosing contact allergy, but the use of patch testing in detecting hypersensitivity to implant materials is controversial. The frequency of positive patch tests increases, however, when more haptens are tested.

Metal alloys are also used in other procedures; including dental implants, cardiovascular stents, and gastrointestinal wire mesh stents. There is insufficient evidence evaluate the clinical utility of

metal allergy testing for these indications In vitro allergy testing is not indicated when there are no contraindications to skin testing or in patients who are successfully being treated for allergies, have mild symptoms and a short allergy season.

### **Leukocyte Histamine Release (LHR)**

Leukocyte histamine release testing is an in vitro test that evaluates the presence of specific IgE antibodies. The test has been proposed for the diagnosis of various allergic conditions, including atopic disorders and stinging insect allergies. Leukocyte histamine release testing detects the release of histamine from basophils in a sample of whole blood exposed to allergens in vitro. It is a cumbersome test typically conducted in research laboratories and has not been studied fully for its predictive value in determining specificity and sensitivity. Its role in the diagnosis and management of allergic disease outside of the investigative setting has not been established.

### **Bead-Based Epitope Assay (BBEA):**

A bead-based epitope assay (BBEA) has been proposed to diagnose and monitor patients with food allergies. The test breaks down allergenic proteins into smaller components, called epitopes. It then measures the reactivity of a patient's IgE/IgG4 levels to each epitope to generate a detailed reactivity profile that can be used by clinicians to manage the allergy. There are several IgE epitope mapping methods based on the binding of IgE molecules to peptides that are derived from the allergen, thereby allowing for the identification of epitopes. The epitope mapping technology of such peptide arrays, by means of immobilized peptides on a surface, have been subjected to substantial development over the last decades. Typically, overlapping peptides of 10–20 amino acid residues are synthesized in parallel, for example, on a glass slide or a nitrocellulose membrane. A few years ago standard peptide synthesis could only synthesize a few hundred peptides, but with the recent technological advances, synthesis of up to 2,100,000 peptides is now a possibility. These advances in peptide arrays have recently allowed for the identification of epitopes on the amino acid level this being able to identify the amino acids within an epitope contributing to the binding to IgE of peanut allergic patients (Broekman, et al., 2015).

AllerGenis™ has developed technology using data-driven machine learning and multiplex immunoassay technology that is proposed to more precisely diagnose and monitor patients with food allergies. According to the manufacturer's website, the diagnostic technology subdivides allergenic proteins into smaller peptides, called epitopes, and measures the reactivity of a patient's IgE to these epitopes. The platform uses a high-throughput, Luminex bead-based epitope assay (BBEA) to analyze IgE reactivity to discrete food allergen epitopes (e.g., VeriMAP™ Peanut Dx, VeriMAP™ Peanut Sensitivity).

The evidence in the published peer-reviewed medical literature evaluating the effectiveness of BBEA primarily consists of cohort studies and comparative case control studies with prospective and retrospective designs with relatively small sample sizes (Suprun, et al., 2019; Suárez-Fariñas, et al., 2019; Flinterman, et al., 2008; Shreffler, et al., 2005; Beyer, et al., 2003). More rigorous studies are needed to establish that the bead-based epitope assay improves outcomes compared to alternative testing modalities.

### **Treatment**

Evidence-based clinical practice guidelines support the use of subcutaneous allergen immunotherapy for the management of allergic asthma, allergic rhinitis (with or without conjunctivitis), and stinging insect venom hypersensitivity. Clinical studies do not support the use of allergen immunotherapy for treatment of angioedema, atopic dermatitis, chronic urticaria, and food hypersensitivity. Numerous allergy treatment methods have been proposed as alternatives to subcutaneous allergen immunotherapy, as detailed above. There is insufficient evidence in the published medical literature to demonstrate the safety and efficacy of these alternative treatments.

The allergy treatment recommendations in this Coverage Policy are based primarily on practice parameters developed by a joint task force representing the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology (ACAAI) (Cox, et al., 2011).

### **Subcutaneous Allergen Immunotherapy**

Subcutaneous immunotherapy (SCIT) consists of gradual administration of increasing amounts of allergen to which the individual is sensitive, in order to temper the immune response and alleviate allergic symptoms. Subcutaneous injection immunotherapy is an established form of treatment and may be considered for individuals with symptoms of allergic rhinitis, allergic conjunctivitis, or allergic asthma with natural exposure to allergens and who demonstrate specific IgE antibodies to the relevant allergen(s). SCIT is usually only recommended for the treatment of allergic respiratory disease following a period of pharmacologic management and observation. Factors to be considered in determining treatment include the severity/duration of symptoms, patient preference/acceptability, adherence, medication requirements, response to avoidance measures, and the adverse effects of medications. The expected response to immunotherapy is antigen specific and depends on the accurate identification and selection of component allergens based on the individual's history, exposure and diagnostic test results (skin testing or serum/in-vitro testing). There is insufficient evidence to support the use of allergen immunotherapy for atopic dermatitis, food hypersensitivity, chronic urticarial, or angioedema.

The allergy immunotherapy recommendations in this Coverage Policy are based primarily on practice parameters developed by a joint task force representing the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology (ACAAI) (Cox, et al., 2011)

**Injection Schedules:** There are two phases of allergy immunotherapy administration; the initial build-up phase and the maintenance phase. In the build-up phase, the dose and concentration of allergen immunotherapy extract are increased, and in the maintenance phase, the patient receives an effective therapeutic dose over a period of time. With the most common build-up phase schedule, injections are administered one to three times per week. With this schedule, patients usually reach a maintenance dose in three to six months, depending on the starting dilution and occurrence of reactions. If a systemic reaction occurs, immunotherapy may be discontinued, or if continued, the dose is reduced. Immunotherapy schedules may need to be adjusted for a variety of reasons, including missed visits, high pollen or mold seasons, addition of a new allergen, or systemic reaction.

Once a patient reaches the maintenance phase, the interval between injections can be progressively increased as tolerated, to an interval of up to four weeks for inhalant allergens and up to eight weeks for venom. The effective therapeutic dose or maintenance dose is the dose that provides therapeutic efficacy without significant adverse local or systemic reactions. Three to five years of maintenance therapy is generally considered optimal for maximum clinical benefit.

### **Accelerated Immunotherapy Schedules**

Accelerated immunotherapy schedules include cluster immunotherapy and rush immunotherapy. Accelerated immunotherapy schedules may permit an individual to reach a maintenance dose sooner but are associated with a higher risk of systemic reactions for inhalant allergens, especially with high-risk patients (e.g., those with markedly positive prick/puncture or in vitro IgE test responses).

**Cluster immunotherapy:** With cluster immunotherapy, several injections (usually two or three) are administered during each visit in order to achieve a maintenance dose more rapidly than

conventional schedules. In cluster immunotherapy, several injections at increasing doses (generally 2–3 per visit) are administered sequentially in a single day of treatment on nonconsecutive days. The maintenance dose is usually achieved more rapidly than with a conventional (single injection per session) schedule. Cluster schedules usually include fewer total injections than are used with conventional schedules and permit a patient to reach a maintenance dose sooner, usually in one to four weeks.

**Rush Immunotherapy:** With rush immunotherapy, incremental doses of allergen are administered at varying intervals between 15 and 60 minutes over one to three days until the target therapeutic dose is achieved. Rush immunotherapy for inhalant allergies may be associated with a significant risk of systemic reactions. Rush schedules for stinging Hymenoptera venom immunotherapy are not associated with an increased incidence of systemic reactions, however.

**Sublingual Antigen Extract Drop Immunotherapy Preparations:** Please refer to Pharmacy Coverage Policy: Sublingual Allergen Immunotherapy for information regarding FDA-approved sublingual allergen immunotherapy.

Standardized antigen extract drop immunotherapy preparations administered under the tongue allows absorption through the sublingual mucosa. This therapy has been proposed for the treatment of patients with asthma and/or allergic rhinitis. Questions remain about the optimal dosing, duration of treatment, and the use of multiple allergens. Because of mixed study results, the therapy is controversial. There is insufficient evidence in the published, peer-reviewed scientific literature regarding improved outcomes using this therapy. Clinical trial data comparing sublingual antigen extract drop immunotherapy with other immunotherapy treatments are also lacking. Further, professional society support in the form of published consensus guidelines is lacking. In a Practice Parameter Update (2017) regarding the use of liquid extract drops the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the American College of Allergy, Asthma, and Immunology (ACAAI) note that although alternative regimens and preparations for liquid sublingual immunotherapy or use of specific sublingual drops have been proposed and may be used off-label, these products and formulations have not been systematically studied in a rigorous manner in US populations. Use of such products or formulations is without recommendation for any current particular indication in the US populations and is not endorsed. (Strength of Recommendation: Strong; Evidence: D: Directly based on category IV evidence or extrapolated recommendation from categories I, II, or III evidence.) At present there are no U.S. Food and Drug Administration (FDA)-approved sublingual antigen extract drop preparations.

Several meta-analyses and systematic reviews have examined outcomes with subcutaneous antigen extract drop immunotherapy (Fortescue, et al., 2020; Calderon, et al., 2011; DiBona, et al., 2010; Calamita, et al., 2006; Wilson, et al., 2004; update Radulovic, et al., 2010). Other studies have evaluated the comparative clinical effectiveness of this immunotherapy compared with subcutaneous immunotherapy, placebo and other interventions for the treatment of allergic rhino-conjunctivitis and/or asthma (Chelladurai and Lin, 2014; de Bot, et al., 2013). Study authors noted randomized controlled trials with head-to-head direct comparisons of subcutaneous immunotherapy and sublingual antigen extract drop immunotherapy are needed to strengthen the evidence base. Indirect comparisons of treatment options have many limitations and must be taken into consideration for clinical decision making.

Liu et al. (2019) conducted a multi-center, double-blind, randomized placebo-controlled trial with four parallel groups to evaluate the efficacy and safety of sublingual immunotherapy (SLIT) with *Dermatophagoides farinae* (*D. farina*) drops on patients with house dust mites (HDM) induced atopic dermatitis (AD). The study included patients (n=239) aged 18–60 years, a severity score of atopic dermatitis between 10 and 40 on the scoring atopic dermatitis (SOCRAD) scale, and a

positive skin prick test results to *D. farinae* stimulation. Patients were randomly divided into four groups: placebo (n=60), high-dose sublingual *D. farinae* drops (n=60), medium-dose sublingual *D. farinae* drops (n=60) and low-dose sublingual *D. farinae* drops (n=59). Treatment was conducted by two phases: up-dosing phase (1st–10th weeks) and maintenance phase (11th–36th weeks). In up-dosing phase, patients received low to high dose of sublingual *D. farinae* drops or placebo treatment. In the maintenance phase, patients took a high dose of sublingual *D. farinae* drops or placebo daily. The primary outcome assessed the therapeutic efficacy and safety of SLIT drops. Patients were assigned to receive relevant treatment for 36 weeks with follow-ups at four, 10, 16, 24 and 36 weeks. The therapeutic efficacy of SLIT with *D. farinae* drops was assessed using the SCORAD scale, the use of concomitant drugs to relieve clinical symptoms in maintenance phase, the dermatology life quality index (DLQI) and the skin lesion area. The safety was evaluated by adverse events (AE) and general clinical laboratory evaluations. 48 cases withdrew before the end of study. There were no significant differences in withdraw rates between the placebo group and *D. farinae* Drops groups. There was significant decreases in scoring atopic dermatitis and total medication score in the medium-dose and high-dose *D. farinae* drops groups. At the sixth visit, the skin lesion area showed a statistically significant difference between high-dose/medium-dose *D. farinae* drops group and placebo group ( $p < 0.05$ ). Most adverse events were minimal, and no life-threatening adverse drug reactions occurred. Author noted limitations included short term follow-up and children were not included as test subjects. The authors concluded that the study demonstrated the beneficial effect of SLIT with high or medium dose *D. farinae* drops on AD, and the treatment was well tolerated. However, further studies should include a longer time frames and a more suitable *D. farina* drops dosage.

Pfaar et al. (2019) conducted a parallel-group, multicenter, double-blind, randomized placebo-controlled trial to investigate the efficacy and safety of sublingual high-dose liquid birch pollen extract (40,000 allergy units native [AUN]/mL) in adults with birch pollen allergy. The study included adult patients (n=406) aged 18-65 years with moderate-to-severe birch pollen-induced allergic rhinoconjunctivitis with or without mild-to-moderate controlled asthma. Patients were randomized into the active treatment group (n=208) or the placebo group (n=198). Treatment was started three to six months before the birch pollen season and continued co-seasonally during the pollen season followed by an open-label safety extension period over six months that included 343 patients treated exclusively with the active product (n=169/active treatment group and n=174/placebo group). The primary outcome measured the difference in mean combined symptom and medication score (CSMS) between the active and placebo treatment groups. The CSMS is the European Academy of Allergy and Clinical Immunology (EAACI) recommended end point for pivotal studies. Primary outcome analysis was carried out in the intention-to-treat (ITT) population (n=357), with 179 patients in the active treatment group and 178 patients in the placebo group. The Secondary outcomes assessed quality-of-life, immunologic parameters, and safety. Thirty-two patients were lost to follow-up primarily due to the development of adverse events (AEs). Primary efficacy results demonstrated a significant ( $p < 0.0001$ ) and clinically relevant (32%) reduction in the combined symptom and medication score compared with placebo after three to six months of sublingual allergen immunotherapy (SLIT) in the intention to treat (ITT) population. Significantly better rhinoconjunctivitis quality-of-life scores ( $p < 0.0001$ ) and the patient's own overall assessment of his or her health status, including the visual analog scale score (Euro Quality of Life Visual Analogue Scale;  $p = 0.0025$ ), were also demonstrated. In total, a good safety profile of SLIT was observed. The local and systemic treatment-emergent adverse events (TEAEs) in the double blind period of the study totaled 342 local reactions in 165 (40.6%) patients and 83.0% of all reactions were mild. Four (1.9%) patients of the active treatment group experienced at least one severe local reaction. Local and systemic adverse reactions were mainly of mild intensity and well controlled in the open label extension, 123 of 343 patients reported a local reaction, 88 of whom belonged to the former placebo group. Most local reactions were of mild-to-moderate intensity (> 97%). Regarding clinical and laboratory safety parameters, no safety issues were observed.

On behalf of the Agency for Healthcare Research and Quality, Lin et al. (2013) and colleagues reported results of a comparative effectiveness review of 60 studies comparing sublingual antigen extract drop therapy to placebo or another intervention for the treatment of allergic rhinoconjunctivitis and/or asthma. Authors note overall quality of evidence is assessed to be low to moderate due in part to limitations with the description of allocation concealment in some studies, moderate statistical heterogeneity and possible publication bias. Large definitive trials are required as well as head-to-head comparative studies with currently available anti-allergic drugs. Further studies evaluating the mechanisms of sublingual antigen extract drop immunotherapy preparations are needed as is a need to develop and validate standard instruments, such as questionnaires with adequate psychometrical properties. There is need for further large rigorously designed studies that examine long-term effectiveness after discontinuation of treatment and establish the cost-effectiveness of sublingual antigen extract drop immunotherapy preparations.

In a Cochrane review, Wilson et al. (2004; update Radulovic, et al., 2010), conducted a systematic review and meta-analysis of sublingual antigen extract drop immunotherapy for the treatment for allergic rhinitis. The authors identified 22 randomized controlled trials involving 979 patients. Only two of the studies compared injection therapy with sublingual extract drop therapy. The studies reported similar improvements in symptoms and medication requirements. The authors found heterogeneity in the findings, due to varying methods used to administer sublingual extract drop therapy and different clinical response scoring systems. Overall, sublingual antigen extract drop immunotherapy was followed by a significant reduction in mean symptom scores ( $p=0.002$ ) and medication use ( $p=0.0003$ ) when compared to placebo therapy. There were no significant variations in response to the use of different allergens in the studies. The authors noted total amount of allergen delivered may be a determinant of success, but the increasing time duration of sublingual extract drop therapy did not clearly increase efficacy. Sublingual extract drop therapy did not appear to be effective in studies limited to allergic children; however, the numbers of children in such studies were too small to draw definitive conclusions. The subgroup analyses did not suggest a benefit of treatment in any particular patient or disease group. The updated review of 2010 resulted in no change to the conclusions.

## Medicare Coverage Determinations

	<b>Contractor</b>	<b>Determination Name/Number</b>	<b>Revision Effective Date</b>
NCD	National	Food Allergy Testing and Treatment (110.11)	10/31/1988
NCD	National	Antigens Prepared for Sublingual Administration (110.9)	11/17/1996
NCD	National	Challenge Ingestion Food Testing (110.12)	08/01/1978
NCD	National	Cytotoxic Food Tests (110.13)	08/05/1985
LCD	CGS Administrators, LLC	RAST Type Tests (L34063)	08/03/2023
LCD	CGS Administrators, LLC	Allergy Immunotherapy (L32553)	11/02/2023
LCD	National Government Services, Inc.	RAST Type Tests (L33591)	11/07/2019
LCD	Novitas Solutions, Inc	Allergy Testing (L36241)	07/11/2021

	<b>Contractor</b>	<b>Determination Name/Number</b>	<b>Revision Effective Date</b>
LCD	Novitas Solutions, Inc	Allergen Immunotherapy (L36240)	07/11/2021
LCD	Noridian Healthcare Solutions, LLC	Allergy Testing (L34313)	10/01/2019
LCD	First Coast Service Options, Inc.	Allergy Testing (L33261)	07/11/2021
LCD	First Coast Service Options, Inc.	Allergen Immunotherapy (L37800)	07/11/2021
LCD	Wisconsin Physicians Service Insurance Corporation	Allergy Testing (L36402)	10/01/2022
LCD	Wisconsin Physicians Service Insurance Corporation	Allergy Immunotherapy (L36408)	10/26/2023
LCD	Palmetto GBA	Allergy Skin Testing (L33417)	04/15/2021

Note: Please review the current Medicare Policy for the most up-to-date information.  
(NCD = National Coverage Determination; LCD = Local Coverage Determination)

## Coding Information

### Notes:

1. This list of codes may not be all-inclusive since the American Medical Association (AMA) and Centers for Medicare & Medicaid Services (CMS) code updates may occur more frequently than policy updates.
2. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

### Testing

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<b>CPT®* Codes</b>	<b>Description</b>
86003	Allergen specific IgE; quantitative or semiquantitative, crude allergen extract, each
86005	Allergen specific IgE; qualitative, multiallergen screen (eg, disk, sponge, card)
86008	Allergen specific IgE; quantitative or semiquantitative, recombinant or purified component, each
86353	Lymphocyte transformation, mitogen (phytomitogen) or antigen induced blastogenesis
95004	Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests

<b>CPT®* Codes</b>	<b>Description</b>
95017	Allergy testing, any combination of percutaneous (scratch, puncture, prick) and intracutaneous (intradermal), sequential and incremental, with venoms, immediate type reaction, including test interpretation and report, specify number of tests
95018	Allergy testing, any combination of percutaneous (scratch, puncture, prick) and intracutaneous (intradermal), sequential and incremental, with drugs or biologicals, immediate type reaction, including test interpretation and report, specify number of tests
95024	Intracutaneous (intradermal) tests with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests
95027	Intracutaneous (intradermal) tests, sequential and incremental, with allergenic extracts for airborne allergens, immediate type reaction, including test interpretation and report, specify number of tests
95028	Intracutaneous (intradermal) tests with allergenic extracts, delayed type reaction, including reading, specify number of tests
95044	Patch or application test(s) (specify number of tests)
95052	Photo patch test(s) (specify number of tests)
95070	Inhalation bronchial challenge testing (not including necessary pulmonary function tests), with histamine, methacholine, or similar compounds
95076	Ingestion challenge test (sequential and incremental ingestion of test items, eg, food, drug or other substance); initial 120 minutes of testing
95079	Ingestion challenge test (sequential and incremental ingestion of test items, eg, food, drug or other substance); each additional 60 minutes of testing (List separately in addition to code for primary procedure)

**Considered Experimental/Investigational/Unproven:**

<b>CPT®* Codes</b>	<b>Description</b>
86343	Leukocyte histamine release test (LHR)

**Not Covered or Reimbursable:**

<b>CPT®* Codes</b>	<b>Description</b>
0165U	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and probability of peanut allergy
0178U	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction

**Treatment**

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**



<b>CPT®* Codes</b>	<b>Description</b>
95115	Professional services for allergen immunotherapy not including provision of allergenic extracts; single injection
95117	Professional services for allergen immunotherapy not including provision of allergenic extracts; 2 or more injections
95120	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; single injection
95125	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 2 or more injections
95130	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; single stinging insect venom
95131	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 2 stinging insect venoms
95132	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 3 stinging insect venoms
95133	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 4 stinging insect venoms
95134	Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 5 stinging insect venoms
95144	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, single dose vial(s) (specify number of vials)
95145	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); single stinging insect venom
95146	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 2 stinging insect venoms
95147	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 3 stinging insect venoms
95148	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 4 stinging insect venoms
95149	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 5 stinging insect venoms
95165 <sup>†</sup>	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; single or multiple antigens (specify number of doses)
95170	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; whole body extract of biting insect or other arthropod (specify number of doses)
95180	Rapid desensitization procedure, each hour (eg, insulin, penicillin, equine serum)

**<sup>†</sup>Note: Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, single or multiple antigens that exceeds a maximum of 150 doses per year (i.e., rolling 12 months) are not covered or reimbursable.**

## **Sublingual Antigen Extract Drop Immunotherapy Preparations**

**Not covered or reimbursable when used to report sublingual antigen extract drop immunotherapy preparations:**

<b>CPT®* Codes</b>	<b>Description</b>
95165	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; single or multiple antigens (specify number of doses)
95199	Unlisted allergy/clinical immunologic service or procedure

**\*Current Procedural Terminology (CPT®) ©2023 American Medical Association: Chicago, IL.**

## **References**

1. Abramson MJ, Puy RM, Welner JM. Injection allergen immunotherapy for asthma. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD001186.
2. Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, et al. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Allergy. 2019 May;74(5):855-873.
3. AllerGenis 2023. Accessed Mar 28, 2024. Available at URL address: <https://www.allergen.com/>
4. Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol. 2009 Jul;124(1):150-156.e1-5.
5. American Academy of Orthopaedic Surgeons website. Skin patch testing and associated total knee outcomes. Accessed Mar 28, 2024. Available at URL address: [https://www5.aaos.org/cc\\_files/aaosorg/research/committee/biomed/bme\\_se\\_2013.pdf](https://www5.aaos.org/cc_files/aaosorg/research/committee/biomed/bme_se_2013.pdf)
6. American Academy of Otolaryngic Allergy, Clinical Care Statements. 2020. Accessed Mar 28, 2024. Available at URL address: <https://aaoallergy.org/practice-2/clinical-care-statements-2020/>
7. American Board of Internal Medicine's (ABIM) Foundation Choosing Wisely® Initiative. American Academy of Asthma, Allergy, and Immunology. Ten Things Physicians and Patients Should Question. April 4, 2012 (1-5) and March 3, 2014 (6-10); last reviewed 2021. Accessed February 1, 2023. Available at URL address: <https://www.choosingwisely.org/societies/american-academy-of-allergy-asthma-immunology/>
8. American Board of Internal Medicine's (ABIM) Foundation Choosing Wisely® Initiative. American Academy of Dermatology. August 19, 2015, updated 2021. Accessed Mar 28, 2024. Available at URL address: <https://www.choosingwisely.org/clinician-lists/skin-prick-blood-tests-to-diagnose-dermatitis-or-eczema/>

9. American Board of Internal Medicine's (ABIM) Foundation Choosing Wisely® Initiative. American Academy of Pediatrics. March 17, 2014, updated 2022. Accessed February 1, 2023 Mar 28, 2024. Available at URL address: <https://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-screening-panels-for-food-allergies/>
10. Ansotegui IJ, Melioli G, Canonica GW, Caraballo L, Villa E, Ebisawa M, et al. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. *World Allergy Organ J.* 2020 Feb 25;13(2):100080.
11. Baba SM, Rasool R, Gull A, Qureshi TA, Beigh AH, Qadri Q, et al. Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir. *Front Immunol.* 2021 Oct 13;12:723814.
12. Bégin P, Chan ES, Kim H, Wagner M, Cellier MS, Favron-Godbout C, Abrams EM, et al. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy. *Allergy Asthma Clin Immunol.* 2020 Mar 18;16:20.
13. Berg EA, Platts-Mills TA, Commins SP. Drug allergens and food--the cetuximab and galactose- $\alpha$ -1,3-galactose story. *Ann Allergy Asthma Immunol.* 2014 Feb;112(2):97-101.
14. Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2008, updated 2014. *J Allergy Clin Immunol.* 2014 May;133(5):1270-7. Accessed February 1, 2023 Mar 28, 2024. Available at URL address: <https://www.aaaai.org/Allergist-Resources/Statements-Practice-Parameters/Practice-Parameters-Guidelines>
15. Beyer K, Ellman-Grunther L, Järvinen KM, Wood RA, Hourihane J, Sampson HA. Measurement of peptide-specific IgE as an additional tool in identifying patients with clinical reactivity to peanuts. *J Allergy Clin Immunol.* 2003 Jul;112(1):202-7.
16. Bogacz-Piaseczyńska A, Bożek A. The Effectiveness of Allergen Immunotherapy in Adult Patients with Atopic Dermatitis Allergic to House Dust Mites. *Medicina (Kaunas).* 2022 Dec 21;59(1):15.
17. Bognanni A, Chu DK, Firmino RT, Arasi S, Waffenschmidt S, Agarwal A, et al. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guideline update - XIII - Oral immunotherapy for CMA - Systematic review. *World Allergy Organ J.* 2022 Sep 8;15(9):100682.
18. Bovermann X, Ricklefs I, Vogelberg C, Klimek L, Kopp MV. Accelerated Dose Escalation with 3 Injections of an Aluminum Hydroxide-Adsorbed Allergoid Preparation of 6 Grasses Is Safe for Children and Adolescents with Moderate to Severe Allergic Rhinitis. *Int Arch Allergy Immunol.* 2021;182(6):524-534.
19. Boyce JA, Assa'ad A, Burks AW, Jones SM, Sampson HA, Wood RA, et al. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. *Journal of Allergy and Clinical Immunology* 2010;126(6):1105-1118.
20. Broekman HCH, Eiwegger T, Upton J, Bøgh KL. IgE – the main player of food allergy, *Drug Discov Today: Dis Model* 2015, Volumes 17-18: 37-44.

21. Brooks GD, Bush RK. Allergens and other factors important to atopic disease. In: Grammer LC, Greenberger PA, editors. In: Patterson's allergic diseases, 7th ed. Lippincott, Williams & Wilkins; 2009.
22. Brozek JL, Firmino RT, Bognanni A, Arasi S, Ansotegui I, Assa'ad AH, et al. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guideline update - XIV - Recommendations on CMA immunotherapy. World Allergy Organ J. 2022 Apr 23;15(4):100646.
23. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013 May;131(5):1288-96.e3.
24. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy. 2006 Oct;61(10):1162-72.
25. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001936.
26. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD007685.
27. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009 Dec;64 Suppl 91:1-59.
28. Chelladurai Y, Lin SY. Effectiveness of subcutaneous versus sublingual immunotherapy for allergic rhinitis: current update. Curr Opin Otolaryngol Head Neck Surg. 2014 Jun;22(3):211-5.
29. Commins SP, Platts-Mills TA. Delayed anaphylaxis to red meat in patients with IgE specific for galactose alpha-1,3-galactose (alpha-gal). Curr Allergy Asthma Rep. 2013 Feb;13(1):72-7.
30. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009 Nov;64(11):1570-9.
31. Costa TMR, Carneiro FM, Oliveira KAS, Souza MFB, Avelino MAG, Wastowski IJ. Rhinophototherapy, an alternative treatment of allergic rhinitis: Systematic review and meta-analysis. Braz J Otorhinolaryngol. 2021 Nov-Dec;87(6):742-752.
32. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006 May;117(5):1021-35.
33. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-55. Accessed February 1, 2023 Mar 28, 2024. Available at URL

address: <https://www.aaaai.org/Allergist-Resources/Statements-Practice-Parameters/Practice-Parameters-Guidelines>

34. Croft AM, Bager P, Kumar S. Helminth therapy (worms) for allergic rhinitis. *Cochrane Database Syst Rev.* 2012 Apr 18;(4):CD009238.
35. d'Art YM, Forristal L, Byrne AM, Fitzsimons J, van Ree R, DunnGalvin A, et al. Single low-dose exposure to cow's milk at diagnosis accelerates cow's milk allergic infants' progress on a milk ladder programme. *Allergy.* 2022 Sep;77(9):2760-2769.
36. Dantzer J, Dunlop J, Psoter KJ, Keet C, Wood R. Efficacy and safety of baked milk oral immunotherapy in children with severe milk allergy: A randomized, double-blind, placebo-controlled phase 2 trial. *J Allergy Clin Immunol.* 2022 Apr;149(4):1383-1391.e17.
37. Darsow U, Vieluf D, Ring J. Evaluating the relevance of aeroallergen sensitization in atopic eczema with the atopy patch test: a randomized, double-blind multicenter study. *J Am Acad Dermatol.* 1999 Feb;40(2 Pt 1):87-93.
38. Davis CM, Apter AJ, Casillas A, Foggs MB, Louisias M, Morris EC, et al. Health disparities in allergic and immunologic conditions in racial and ethnic underserved populations: A Work Group Report of the AAAAI Committee on the Underserved. *J Allergy Clin Immunol.* 2021 May;147(5):1579-1593.
39. de Bot CM, Moed H, Berger MY, et al. Sublingual immunotherapy in children with allergic rhinitis: quality of systematic reviews. *Pediatr Allergy Immunol* 2011; 22(6):548-58. *Prim Care Respir J.* 2013 Jun;22(2):155-60.
40. de Bot CM, Röder E, Pols DH, Bindels PJ, van Wijk RG, van der Wouden JC, et al. Sensitisation patterns and association with age, gender, and clinical symptoms in children with allergic rhinitis in primary care: a cross-sectional study. *Prim Care Respir J.* 2013 Jun;22(2):155-60.
41. De Schryver S, Mazer B, Clarke AE, St Pierre Y, Lejtenyi D, Langlois A, et al. Adverse Events in Oral Immunotherapy for the Desensitization of Cow's Milk Allergy in Children: A Randomized Controlled Trial. *J Allergy Clin Immunol Pract.* 2019 Jul-Aug;7(6):1912-1919. doi: 10.1016/j.jaip.2019.02.007.
42. de Silva D, Rodríguez Del Río P, de Jong NW, Khaleva E, Singh C, Nowak-Węgrzyn A, et al. Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis. *Allergy.* 2022 Jun;77(6):1852-1862.
43. de Waard van der Spek FB, Darsow U, Mortz CG, Orton D, Worm M, Muraro A, Schmid-Grendelmeier P, et al. de Waard position paper for practical patch testing in allergic contact dermatitis in children. *Pediatr Allergy Immunol.* 2015 Nov;26(7):598-606.
44. Dente FL, Bacci E, di Franco A, Giannini D, Conti I, Macchioni P. Reproducibility of early and late asthmatic responses to allergen challenge in a large group of asthmatics. *Respir Med.* 2000 May;94(5):41-7.
45. DiBona D, Plaia A, Scafida V, Leto-Barone MS, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. *J Allergy Clin Immunol.* 2010 Sep;126(3):558-66.

46. Dunn Galvin A, Fleischer DM, Campbell DE, O'B Hourihane J, Green TD, Sampson HA, Greenhawt M. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies. *J Allergy Clin Immunol Pract.* 2021 Jan;9(1):216-224.e1.
47. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC). 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. *J Allergy Clin Immunol.* 2020 Dec;146(6):1217-1270. Accessed February 1, 2023 Mar 28, 2024. Available at URL address: <https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines>
48. Flinterman AE, Knol EF, Lencer DA, Bardina L, den Hartog Jager CF, Lin J, Pasmans SG, et al. Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy. *J Allergy Clin Immunol.* 2008 Mar;121(3):737-743.e10.
49. Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. *Cochrane Database Syst Rev.* 2020 Sep 14;9(9):CD011293.
50. Fox RA, Sabo BM, Williams TP, Joffres MR. Intradermal testing for food and chemical sensitivities: a double-blind controlled study. *J Allergy Clin Immunol.* 1999 May;103(5 Pt 1):907-11.
51. Gellrich D, Pfab F, Ortiz M, Binting S, Brinkhaus B, Gröger M. Acupuncture and its effect on cytokine and chemokine profiles in seasonal allergic rhinitis: a preliminary three-armed, randomized, controlled trial. *Eur Arch Otorhinolaryngol.* 2022 Oct;279(10):4985-4995.
52. Golden DB, Demaain J, Moffitt J, Freeman T, Graft D, Tankersley M, Tracy J, et al. Stinging insect hypersensitivity: a practice parameter update 2016. *J Allergy Clin Immunol.* 2017 Jan;118(1):28-54. Accessed February 1, 2023 Mar 28, 2024. Available at URL address: <https://www.aaaai.org/Allergist-Resources/Statements-Practice-Parameters/Practice-Parameters-Guidelines>
53. Granchi D, Cenni E, Giunti A, Baldini N. Metal hypersensitivity testing in patients undergoing joint replacement: a systematic review. *J Bone Joint Surg Br.* 2012 Aug;94(8):1126-34.
54. Granchi D, Cenni E, Tigani D, Trisolino G, Baldini N, Giunti A. Sensitivity to implant materials in patients with total knee arthroplasties. *Biomaterials.* 2008 Apr;29(10):1494-500.
55. Greenhawt M, Oppenheimer J, Nelson M, Nelson H, Lockey R, Lieberman P, et al. Sublingual immunotherapy: A focused allergen immunotherapy practice parameter update. *Ann Allergy Asthma Immunol.* 2017 Mar;118(3):276-282.e2. Accessed Mar 28, 2024. Available at URL address: Peanut allergy diagnosis: A&nbsp;2020 practice parameter update, systematic review, and GRADE analysis (aaaai.org)
56. Hayes Inc. Evidence Analysis Research Brief. Acupuncture for the Treatment of Allergic Rhinitis. Lansdale, PA: Hayes, Inc.; October 2020.

57. He M, Qin W, Qin Z, Zhao C. Acupuncture for allergic rhinitis: a systematic review and meta-analysis. *Eur J Med Res*. 2022 Apr 25;27(1):58.
58. Jappe U, Minge S, Kreft B, Ludwig A, Przybilla B, Walker A, et al. Meat allergy associated with galactosyl- $\alpha$ -(1,3)-galactose ( $\alpha$ -Gal)-Closing diagnostic gaps by anti- $\alpha$ -Gal IgE immune profiling. *Allergy*. 2018 Jan;73(1):93-105.
59. Johansen JD, Aalto-Korte K, Agner T, Andersen KE, Bircher A, Bruze M, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice. *Contact Dermatitis*. 2015 Oct;73(4):195-221. Accessed Mar 28, 2024. Available at URL address: <http://onlinelibrary.wiley.com/doi/10.1111/cod.12432/full>
60. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. *J Allergy Clin Immunol*. 2015 Sep;136(3):556-68.
61. Karali E, Gunes A, Ural A, Akin I, Ozsari E, Kalaycioglu O. Effect of rhinophototherapy on nasal congestion in patients with seasonal allergic rhinitis. *Acta Otorhinolaryngol Ital*. 2021 Apr;41(2):151-158.
62. Kennedy JL, Stallings AP, Platts-Mills TA, Oliveira WM, Workman L, James HR, et al. Galactose- $\alpha$ -1,3-galactose and delayed anaphylaxis, angioedema, and urticaria in children. *Pediatrics*. 2013 May;131(5):e1545-52.
63. Kim EH, Perry TT, Wood RA, Leung DYM, Berin MC, Burks AW, et al. Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy. *J Allergy Clin Immunol*. 2020 Oct;146(4):851-862.e10.
64. Kopp MV, Bovermann X, Klimek L. Accelerated Dose Escalation with Three Injections of an Aluminum Hydroxide-Adsorbed Allergoid Preparation of Six Grasses Is Safe for Patients with Moderate to Severe Allergic Rhinitis. *Int Arch Allergy Immunol*. 2020;181(2):94-102.
65. Kowal K, DuBuske L. Overview of in vitro allergy tests. In: UpToDate, Bochner BS (Ed), UpToDate, Waltham, MA. Literature review current through: January 2023. Topic last updated: May 3, 2021. Literature current through Feb 2024. Accessed Mar 28, 2024.
66. Kręcis B, Kieć-Świerczyńska M, Chomiczewska-Skóra D. Allergy to orthopedic metal implants - a prospective study. *Int J Occup Med Environ Health*. 2012 Sep;25(4):463-9.
67. Lee SH, Chang GT, Zhang X, Lee H. Acupoint Herbal Patching for Asthma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Medicine (Baltimore)*. 2016 Jan;95(2):e2439.
68. Lin SY, Azar A, Suarez-Cuervo C, Diette GB, Brigham E, Rice J, et al. The Role of Immunotherapy in the Treatment of Asthma [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Mar. Report No.: 17(18)-EHC029-EF
69. Lin SY, Erekosima N, Kim JM et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. *JAMA* 2013; 309(12):1278-88.
70. Liu L, Chen J, Xu J, Yang Q, Gu C, Ni C, et al. Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study. *Artif Cells Nanomed Biotechnol*. 2019 Dec;47(1):3540-3547.

71. Lytvyakova LI, Baraniuk JN. Nasal provocation testing: a review. *Ann Allergy Asthma Immunol.* 2001 Apr;86(4):355-64.
72. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. *J Allergy Clin Immunol.* 2010 Nov;126(5):969-75.
73. Morrow EH, Sampson HA. Dose-response in double-blind, placebo-controlled oral food challenges in children with atopic dermatitis. *J Allergy Clin Immunol.* 2000 Mar;105(3):582-6.
74. Nahm DH, Kim ME, Kwon B, Cho SM, Ahn A. Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis. *Yonsei Med J.* 2016 Nov;57(6):1420-6.
75. Nieto A, Mazon A, Pamies R, Bruno L, Navarro M, Montanes A. Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses. *J Allergy Clin Immunol.* 2009 Jul;124(1):157-161.e1-32.
76. Pajno GB, Bernardini R, Peroni D, Arasi S, Martelli A, Landi M, et al. Allergen-specific Immunotherapy panel of the Italian Society of Pediatric Allergy and Immunology (SIAIP). Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. *Ital J Pediatr.* 2017 Jan 23;43(1):13.
77. Palosuo K, Karisola P, Savinko T, Fyhrquist N, Alenius H, Mäkelä MJ. A Randomized, Open-Label Trial of Hen's Egg Oral Immunotherapy: Efficacy and Humoral Immune Responses in 50 Children. *J Allergy Clin Immunol Pract.* 2021 May;9(5):1892-1901.e1
78. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, Canonica GW. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. *Chest.* 2008 Mar;133(3):599-609.
79. Pfaar O, Bachert C, Kuna P, Panzner P, Džupinová M, Klimek L, et al. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma. *J Allergy Clin Immunol.* 2019;143(3):970-977.
80. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. *Cochrane Database of Systematic Reviews* 2010, Issue 12. Art. No.: CD002893.
81. Saleh H, Embry S, Nauli A, Atyia S, Krishnaswamy G. Anaphylactic reactions to oligosaccharides in red meat: a syndrome in evolution. *Clin Mol Allergy.* 2012 Mar 7;10(1):5.
82. Sampson HA, Aceves S, Bock SA, James J, Jones S, Lang D, Nadeau K, Food allergy: A practice parameter update-2014. *J Allergy Clin Immunol.* 2014 Aug 28. pii: S0091-6749(14)00672-1. Accessed Mar 28, 2024. Available at URL address: <https://www.aaaai.org/Allergist-Resources/Statements-Practice-Parameters/Practice-Parameters-Guidelines>
83. Schafer T, Hoelscher B, Adam H, Ring J, Wichman HE, Heinrich J. Hay fever and predictive value of prick test and specific IgE antibodies: A prospective study in children. *Pediatr Allergy Immunol.* 2003 Apr;14(2):120-9.



84. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical practice guideline: Allergic rhinitis. *Otolaryngol Head Neck Surg.* 2015 Feb;152(1 Suppl):S1-43. American Academy of Otolaryngology—Head and Neck Surgery. Clinical Practice Guideline: Allergic Rhinitis. Accessed Mar 28, 2024. Available at URL address: <https://www.entnet.org/quality-practice/quality-products/clinical-practice-guidelines/allergic-rhinitis/>
85. Seidenberg J, Pajno GB, Bauer CP, La Grutta S, Sieber J. Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents. *J Investig Allergol Clin Immunol.* 2009;19(2):125-31
86. Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J, et al. Atopic dermatitis: a practice parameter update 2012. *J Allergy Clin Immunol.* 2013 Feb;131(2):295-9.e1-27. Accessed Mar 28, 2024. Available at URL address: <https://www.aaaai.org/practice-resources/statements-and-practice-parameters/practice-parameter-guidelines>
87. Senti G, Graf N, Haug S, Rüedi N, von Moos S, Sonderegger T, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. *J Allergy Clin Immunol.* 2009 Nov;124(5):997-1002. Epub 2009 Sep 5.
88. Severino MG, Cortellini G, Bonadonna P, Francescato E, Panzini I, Macchia D, et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. *J Allergy Clin Immunol.* 2008 Jul;122(1):44-8.
89. Shaker MS, Wallace DV, Golden DBK, Oppenheimer J, Bernstein JA, Campbell RL, et al. Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. *J Allergy Clin Immunol.* 2020 Apr;145(4):1082-1123. Accessed Mar 28, 2024. Available at URL address: <https://www.aaaai.org/practice-resources/statements-and-practice-parameters/practice-parameter-guidelines>
90. Shreffler WG, Lencer DA, Bardina L, Sampson HA. IgE and IgG4 epitope mapping by microarray immunoassay reveals the diversity of immune response to the peanut allergen, Ara h 2. *J Allergy Clin Immunol.* 2005 Oct;116(4):893-9.
91. Sola Martínez FJ, Barranco Jiménez RM, Martín García C, Senent Sánchez C, Blanco Guerra C, Fernández-Rivas M, et al. Intradermal Phleum pratense allergoid immunotherapy. Double-blind, randomized, placebo-controlled trial. *Clin Exp Allergy.* 2020 Dec;50(12):1352-1361.
92. Su L, Meng L, Chen R, Wu W, Peng B, Man L. Acupoint Application for Asthma Therapy in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Forsch Komplementmed.* 2016;23(1):16-21.
93. Suárez-Fariñas M, Suprun M, Chang HL, Gimenez G, Grishina G, Getts R, Nadeau K, Wood RA, Sampson HA. Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles. *J Allergy Clin Immunol.* 2019 Mar;143(3):1038-1046.
94. Suprun M, Getts R, Raghunathan R, Grishina G, Witmer M, Gimenez G, et al. Novel Bead-Based Epitope Assay is a sensitive and reliable tool for profiling epitope-specific antibody repertoire in food allergy. *Sci Rep.* 2019 Dec 5;9(1):18425.

95. Suprun M, Kearney P, Hayward C, Butler H, Getts R, Sicherer SH, et al. Predicting probability of tolerating discrete amounts of peanut protein in allergic children using epitope-specific IgE antibody profiling. *Allergy*. 2022 Oct;77(10):3061-3069.
96. Thyssen JP, Menné T, Schalock PC, Taylor JS, Maibach HI. Pragmatic approach to the clinical work-up of patients with putative allergic disease to metallic orthopaedic implants before and after surgery. *Br J Dermatol*. 2011 Mar;164(3):473-8.
97. Tsai M, Mukai K, Chinthrajah RS, Nadeau KC, Galli SJ. Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE. *J Allergy Clin Immunol*. 2020 Mar;145(3):885-896.e6.
98. Wilson DR, Torres Lima M, Durham SR. Sublingual immunotherapy for allergic rhinitis (Cochrane Review). In: *The Cochrane Library*, Issue 6, 2004
99. Wilson JM, Platts-Mills TAE. IgE to galactose- $\alpha$ -1,3-galactose and the  $\alpha$ -Gal syndrome: Insights from basophil activation testing. *J Allergy Clin Immunol*. 2019 Jan;143(1):101-103.
100. Wilson JM, Schuyler AJ, Workman L, Gupta M, James HR, Posthumus J, et al. Investigation into the  $\alpha$ -Gal syndrome: Characteristics of 261 children and adults reporting red meat allergy. *J Allergy Clin Immunol Pract*. 2019 Mar 30. pii: S2213-2198(19)30314-9.

## Revision Details

Type of Revision	Summary of Changes	Date
Focused Review	<ul style="list-style-type: none"> <li>• Added policy statements regarding testing limits on allergy testing and preparation of allergen immunotherapy.</li> <li>• Removed the not medically necessary policy statement for in vitro allergy testing and subcutaneous allergen immunotherapy.</li> <li>• Updated the experimental/investigational or unproven policy statement for allergy testing.</li> </ul>	12/03/2023
Annual Review	<ul style="list-style-type: none"> <li>• No changes to coverage.</li> </ul>	05/15/2024

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.